Literature DB >> 21871467

Nasal application of neuropeptide S reduces anxiety and prolongs memory in rats: social versus non-social effects.

Michael Lukas1, Inga D Neumann.   

Abstract

Recent studies demonstrated potent behavioral effects of centrally applied neuropeptide S (NPS) in mice and rats. These include increased arousal and wakefulness, facilitation of fear extinction and object memory consolidation and anxiolysis. Here, we compared the effects of NPS on both social and non-social memory, in male rats, and on social preference/social anxiety versus non-social anxiety after either intracerebroventricular (icv) or nasal application. Intranasal application of neuropeptides has been successfully employed to alter behavioral parameters in humans and rodents, but studies concerning nasal application of NPS are lacking so far. First, we confirmed the facilitatory effect of icv NPS (1 nmol) on object discrimination after an inter-exposure interval (IEI) of 240 min. These effects were context-dependent, as icv NPS (1 nmol) did not prolong social memory in a social discrimination paradigm. Second, we confirmed the anxiolytic effect of icv NPS (1 nmol) on the elevated plus-maze, whereas neither icv NPS (1 nmol) nor NPS receptor antagonist (10 nmol) altered social preference/social avoidance behavior. Third, nasal NPS (4-40 nmol applied topically on the rhinarium) facilitated object discrimination in a dose-dependent manner. Also, the anxiolytic effect of NPS on the elevated plus-maze could be confirmed after nasal administration (40 nmol). In contrast, identical doses of subcutaneously injected NPS failed to produce corresponding behavioral effects in both tests. Our findings provide evidence for memory-enhancing and anxiolytic effects of icv NPS in a non-social context. We could further show that these effects are context-specific, as social memory and social preference behavior remained unchanged after icv NPS. The effects of icv NPS were replicated by nasal application of the neuropeptide. Thus, nasal application of NPS seems to be a useful method in rodents for screening for behavioral or physiological effects before more specific and time-consuming, intracerebral methods are employed, and may represent a viable therapeutic approach for NPS treatment of patients with psychiatric illnesses such as anxiety or panic disorders. This article is part of a Special Issue entitled 'Anxiety and Depression'.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871467     DOI: 10.1016/j.neuropharm.2011.08.016

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  29 in total

1.  Intranasal application of vasopressin fails to elicit changes in brain immediate early gene expression, neural activity and behavioural performance of rats.

Authors:  M Ludwig; V A Tobin; M F Callahan; E Papadaki; A Becker; M Engelmann; G Leng
Journal:  J Neuroendocrinol       Date:  2013-07       Impact factor: 3.627

2.  Neuropeptide S Induces Acute Anxiolysis by Phospholipase C-Dependent Signaling within the Medial Amygdala.

Authors:  Thomas Grund; Inga D Neumann
Journal:  Neuropsychopharmacology       Date:  2017-08-14       Impact factor: 7.853

Review 3.  Nuance and behavioral cogency: How the Visible Burrow System inspired the Stress-Alternatives Model and conceptualization of the continuum of anxiety.

Authors:  James M Robertson; Melissa A Prince; Justin K Achua; Russ E Carpenter; David H Arendt; Justin P Smith; Torrie L Summers; Tangi R Summers; Cliff H Summers
Journal:  Physiol Behav       Date:  2015-07-01

4.  Neuropeptide S receptor gene variation and neural correlates of cognitive emotion regulation.

Authors:  Anne Guhn; Katharina Domschke; Laura D Müller; Thomas Dresler; Florian Eff; Juliane Kopf; Jürgen Deckert; Andreas Reif; Martin J Herrmann
Journal:  Soc Cogn Affect Neurosci       Date:  2015-05-13       Impact factor: 3.436

5.  Oxytocin Intranasal Administration Affects Neural Networks Upstream of GNRH Neurons.

Authors:  Mohammad Saied Salehi; Homayoun Khazali; Fariba Mahmoudi; Mahyar Janahmadi
Journal:  J Mol Neurosci       Date:  2017-06-29       Impact factor: 3.444

6.  Central neuropeptide-S administration alleviates stress-induced impairment of gastric motor functions through orexin-A.

Authors:  Mehmet Bülbül; Osman Sinen; Onur Bayramoğlu
Journal:  Turk J Gastroenterol       Date:  2020-01       Impact factor: 1.852

7.  Selective breeding for high anxiety introduces a synonymous SNP that increases neuropeptide S receptor activity.

Authors:  David A Slattery; Roshan R Naik; Thomas Grund; Yi-Chun Yen; Simone B Sartori; Andrea Füchsl; Beate C Finger; Betina Elfving; Uwe Nordemann; Remo Guerrini; Girolamo Calo; Gregers Wegener; Aleksander A Mathé; Nicolas Singewald; Ludwig Czibere; Rainer Landgraf; Inga D Neumann
Journal:  J Neurosci       Date:  2015-03-18       Impact factor: 6.167

Review 8.  Novel transmitters in brain stem vagal neurocircuitry: new players on the pitch.

Authors:  Mehmet Bülbül; R Alberto Travagli
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-29       Impact factor: 4.052

9.  Neuropeptide S differently modulates alcohol-related behaviors in alcohol-preferring and non-preferring rats.

Authors:  Nazzareno Cannella; Marsida Kallupi; Hong Wu Li; Serena Stopponi; Carlo Cifani; Roberto Ciccocioppo; Massimo Ubaldi
Journal:  Psychopharmacology (Berl)       Date:  2016-05-28       Impact factor: 4.530

10.  Neuroleptics Affect Neuropeptide S and NPSR mRNA Levels in the Rat Brain.

Authors:  Artur Pałasz; Ewa Rojczyk
Journal:  J Mol Neurosci       Date:  2015-07-31       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.